Daiichi Sankyo Co. Ltd.

BioCentury’s roundup of translational innovations also includes microglia replacement for neurological disorders and enhanced mRNA vaccine efficacy 

Also in BioCentury’s Clinical Report: Lilly records an oral GLP-1 win, and new targeted radiotherapy data from Telix

At nearly $1.7B, Zealand got $300M more than the prior top cash payment

Plus: Roche partners with Zealand, AZ with Alteogen and more

How the once-dominant cancer company has overhauled its strategy for long-term growth

Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals

Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling

Plus: New chair at Outlook and an update from Elevation

Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another

BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope